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Angiotensin II action in isolated microperfused rabbit afferent arte-
rioles is modulated by flow. We have recently presented evidence that
endogenous nitric oxide (NO) and prostaglandins (PGs) modulate angio-
tensin II (Ang II) action in microperfused afferent arterioles (Af-Arts).
Because flow may be a physiological stimulus of endothelial release of NO
and PGs, we tested the hypothesis that flow through the lumen of the
Af-Art stimulates the endothelium to produce NO and PGs, which in turn
modulate the action of Ang II. We microdissected the terminal segment of
an interlobular artery together with two Af-Arts, their glomeruli and
efferent arterioles (Ef-Art). The two Af-Arts were perfused simulta-
neously from the interlobular artery, while one Ef-Art was occluded. Since
the arteriolar perfusate contained 5% albumin, oncotic pressure built up
in the glomerulus with the occluded Ef-Art and opposed the force of
filtration, resulting in little or no flow through the corresponding Af-Art.
Thus this preparation allowed us to observe Ang II action in free-flow and
non-flow Af-Arts simultaneously. Ang TI-induced constriction was weaker
in free-flow than non-flow Af-Arts, with the luminal diameter decreasing
by 8 2% and 23 3% at iO° M, respectively (P < 0.013 free-flow vs.
non-flow; N = 9). Disrupting the endothelium augmented Ang II action in
free-flow (33 5.1%; P < 0.01 vs. intact endothelium) but not non-flow
Af-Arts (31 5.3%), thus abolishing the differences between them (N =
8). Pretreatment with an inhibitor of either NO synthase (N-nitro-L-
arginine methyl ester) or cyclooxygenase (indomethacin) augmented Ang
II action more in free-flow than non-flow Af-Arts, likewise abolishing the
differences between them. These results suggest that intraluminal flow
modulates the vasoconstrictor action of Ang II in Af-Arts via endo-
thelium-derived NO and PGs. Thus flow may be important in the fine
control of glomerular hemodynamics.
The renin-angiotensin system is important in the regulation of
glomerular hemodynamics and hence sodium and water balances
under both physiological and pathological conditions [1]. Evi-
dence suggests that Ang II action in the glomerular microcircu-
lation is modulated by various autacoid hormones, including
endothelium-derived nitric oxide (NO) and prostaglandins (PGs)
[2—91. Using isolated microperfused glomerular afferent and ef-
ferent arterioles (Af- and Ef-Arts), we have recently shown that
inhibition of NO synthesis significantly augments Ang II action in
the Af-Art but not in the Ef-Art, suggesting that lesser Ang II
sensitivity of the Af-Art may be due to endogenous synthesis of
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NO [3]. In addition, we have presented evidence that PGs produced
in the Af-Art also counteract the vasoconstrictor action of Ang II
[4]. Although these studies suggest that both NO and PGs play an
important role in regulating Ang II action in the Af-Art, the
mechanisms (or factors) that control PG and NO levels are not
clear. It may be that that Ang II directly stimulates endothelial
cells to release NO and/or PGs [10, 11], which in turn attenuate its
constrictor action. An alternative or additional possibility is that
luminal flow in the Af-Arts stimulates the endothelium to produce
and release NO [12—14] and/or PGs [12, 13, 15—17]. Although it is
well known that flow dilates conduit arteries [15, 181, responses of
the microvasculature are remarkably variable and site-specific [19,
20], and it is not known whether flow modulates Ang II action in
the Af-Art, a vascular segment that is important for the control of
glomerular hemodynamics.
The purpose of the present study was to determine: (1) whether
flow modulates AS-Art responses to Ang II; (2) whether an intact
endothelium is needed in order for flow to modulate Mg Il-induced
constriction; and (3) whether NO and/or PGs are involved in such
modulation. To examine these questions directly, we used an in
vitro preparation in which two AS-Arts were microperfused simul-
taneously, one with flow and the other without. Using this
preparation, we examined whether Ang TI-induced constriction
differs between free-flow and non-flow AS-Arts, and whether such
differences can be abolished by disrupting the endothelium or
inhibiting NO or PG biosynthesis.
Methods
Isolation and microperfusion of the renal arterioles
We used a modification of a previously described method to
isolate and microperfuse the renal arterioles [2—4]. Briefly, young
male New Zealand white rabbits (1.5 to 2.0 kg), fed standard
rabbit chow (Ralston Purina, St. Louis, MO, USA) and tap water
ad libitum, were anesthetized with intravenous sodium pentobar-
bital (40 mg/kg) and given an intravenous injection of heparin
(500 U). The kidneys were removed and sliced along the corti-
comedullary axis and slices placed in ice-cold minimum essential
medium (MEM: Gibco, Grand Island, NY, USA) containing 5%
BSA (Sigma, St. Louis, MO, USA). Using a stereomicroscope
(SZH; Olympus, Tokyo, Japan), we microdissected a single sam-
ple consisting of the terminal segment of an interlobular artery
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Fig. 1. Double Af-Art preparation. Abbreviations are: Af-Art, afferent arteriole; Ef-Art, efferent arteriole. Note that since the arteriolar perfusate
contained 5% albumin, oncotic pressure built up in the glomerulus with the occluded Ef-Art and opposed the force of filtration, resulting in little or
no flow through the corresponding Af-Art. Perfusion pressure was measured at the bifurcation of the interlobular artery using Landis' technique
Ef-Arts. The sample was transferred to a temperature-regulated
chamber mounted on an inverted microscope (Diaphot; Nikon)
and the Af-Arts perfused from the distal end of the interlobular
artery. Figure 1 shows a photograph of our preparation. The
interlobular artery was drawn into the holding pipette, after which
the perfusion pipette was advanced into the lumen of the inter-
lobular artery and perfusion was begun. A fine pipette (pressure
pipette) was advanced through the perfusion pipette into the
interlobular artery to the point where it bifurcates into the two
Af-Arts; intraluminal pressure at this point was measured with the
pressure pipette using Landis' technique and maintained at 60 mM
Hg throughout the experiment. The arterioles were perfused with
oxygenated medium 199 containing 5% BSA (M199—5%BSA).
The bath, which was exchanged continuously, was identical to
the arteriolar perfusate except that it contained 0.1% (instead of
5%) BSA. Microdissection and cannulation of the arteriole were
completed within 90 minutes at 8°C, after which the bath was
gradually warmed to 37°C for the rest of the experiment. Once the
temperature stabilized, a 30-minute equilibration period was
allowed. We then occluded one Ef-Art by sucking it into a holding
pipette in a bent position (Fig. 1) and waited for 15 minutes
before taking any measurements. Because the perfusate contained
5% BSA, oncotic pressure increased in the glomerulus with the
occluded Ef-Art, causing ultrafiltration to decrease markedly;
consequently, there was little or no flow through the correspond-
ing Af-Art. We found that this technique causes flow to decrease
by over 96% in isolated Af-Arts. Thus this preparation allowed us
to simultaneously observe one Af-Art with free-flowing perfusate
(free-flow Af-Art) and another with little or no flow (non-flow
Af-Art). Images of the Al-Arts were displayed at magnifications
up to x1,980 and recorded with a video system consisting of a
camera (NC-70; DAGE-MTI), monitor (HR100; DAGE-MTI)
and video recorder (SLV-R5UC; Sony). Luminal diameter of
free-flow and non-flow Al-Arts was measured with an image
analysis system (Fryer, Carpentersville, IL, USA).
Experimental protocols
Responses to Ang II and norepinephrine
We first studied whether flow modulates Ang II action in
Af-Arts. For this, increasing doses of Ang 11(10_Il to i0 M;
Sigma) were added to the bath. Luminal diameter of free-flow and
non-flow Al-Arts was measured immediately before adding Ang
II and observed for at least three minutes at each dose. Since we
found that Ang IT-induced constriction was weaker in free-flow
Al-Arts (Results), we examined whether flow modulates action of
another vasoconstrictor, norepinephrine (10—8 to 10—6 Sigma).
Effect of endothelial disruption
We next tested whether the endothelium plays a role in flow
modulation of Ang II action. Prior to occluding the Ef-Art, eight
sets of Al-Arts were perfused for 10 minutes with M199—5% BSA
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Fig. 2. Change in luminal diameter induced by
(A) Ang II (N 9) and (B) norepinephrine (n =
5) in free-flow (0) and non-flow ( Af-Arts.
Note that Ang It-induced constriction was
significantly stronger in non-flow Af-Arts,
whereas norepinephrine-induced constriction
was not. + = P < 0.013 free-flow versus non-
flow Af-Arts.
containing anti-human factor Vill-related antigen antibody (14.29
mg/mi; Atlantic Antibodies) and 2% guinea pig complement
(Sigma). This was followed by a 20-minute washout period in
which the arterioles were perfused with M199—5% BSA contain-
ing neither antibody nor complement. We have previously dem-
onstrated that this procedure selectively disrupts endothelial cells
without altering vascular smooth muscle cells [21]. Following
endothelial disruption, one Ef-Art was occluded and a 15-minute
equilibration period allowed, after which increasing doses of Ang
II were added to the bath as described in protocol 1. At the end
of the experiment, we confirmed that the Af-Arts did not dilate
in response to iO M acetylcholine, an endothelium-dependent
vasodilator.
Effect of NO synthesis inhibition
We next examined whether NO plays a role in flow modulation
of Ang II action. For this, i0 M nitro-L-arginine methyl ester
(L-NAME), an NO synthesis inhibitor, was added to the arteriolar
perfusate 15 minutes prior to occluding the Ef-Art and main-
tained throughout the experiment. Increasing doses of Ang II
were then added to the bath as described in protocol 1. We have
previously demonstrated that this concentration of L-NAME
abolishes acetylcholine-induced vasodilation in isolated perfused
Af-Arts [2, 3].
Effect of cyclooxygenase inhibition
To determine whether PGs are involved in flow modulation of
Ang II action, we added 5 X i0 M indomethacin, a cyclooxy-
genase inhibitor, to both the bath and arteriolar perfusate prior to
occluding the Ef-Art. The effect of Ang II was then examined as
in protocol 1. We have previously shown that this dose of
indomethacin blocks the effect of iO M arachidonic acid on
renin release in rabbit Af-Arts [22].
Data analysis
Data are expressed as mean SEM. Paired t-tests were used to
examine whether the diameter at a given concentration was
different from the baseline value within each group. Univariate
repeated-measures ANOVA with the Greenhouse-Geisser spheri-
city correction was used to test whether the groups (free-flow vs.
non-flow, or treated vs. non-treated) differed with respect to the
rate of change across the various periods. For this analysis, P <
0.05 was considered significant. If a significant or borderline
interaction effect was detected, Student's two-sample f-test (or
Welch's test in the event of unequal variances) was used to
examine whether the change in diameter at a given concentration
differed between two groups. When more than one measurement
was made, Bonferroni's multiple comparison adjustment was used
to reduce the significance level (Fig. legends).
Results
Dose responses to Ang II and NE
Basal luminal diameter of free-flow and non-flow Af-Arts did
not differ from each other; the mean value was 18.5 0.5 and
18.4 0.8 mm, respectively (N = 9). As shown in Figure 2A, Ang
II caused dose-dependent constriction in both free-flow and
non-flow Af-Arts; however, it was significantly greater in non-flow
Af-Arts. Non-flow Af-Arts began to constrict significantly at Ang
II concentrations as low as 1O_11 M, whereas free-flow Af-Arts did
not constrict until the concentration reached i0 M. In non-flow
Af-Arts, Ang II at 10_la, i09, and j_8 M caused luminal
diameter to decrease to 95.2 1.4% (P < 0.01), 87.8 2.3%
(P < 0.001), 76.7 2.9% (P < 0.001), and 51.2 3.6% (P <
0.001) of baseline, respectively. Corresponding values for free-
flow Af-Arts were 99.5 0.6% (P = NS), 98.0 1.4% (P = NS),
92.2 2.0% (P < 0.005), and 68.4 5.0% (P < 0.001). In
contrast, norepinephrine (added to the bath) produced almost
identical constriction in free-flow and non-flow Af-Arts (Fig. 2B).
Effect of endothelial disruption
Disrupting the endothelium with anti-factor Vill-related anti-
gen antibody/complement did not alter basal luminal diameter of
either free-flow or non-flow Af-Arts; diameter was 17.3 0.6 and
18.6 0.8 mm (N = 8), respectively. Figure 3 depicts responses to
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Fig. 3. Effect of endothelial dismption on Ang
Il-induced constriction in free-flow (A) and non-
flow (B) Af-Arts. Note that endothelial
disruption augmented Ang If-induced
constriction in free-flow but not non-flow Af-
Arts, eliminating the difference between them.
—8 Symbols are: (0) control (N = 9); (•) De-endo(N = 8). *p < 0.001 for control versus
endothelial disruption (De-endo) Af-Arts.
Fig. 4. Change in luminal diameter induced by
Ang II in free-flow (A) and non-flow (B) Af-Arts
in the absence and presence of L-NAME. Note
that L-NAME augmented Ang TI-induced
constriction in free-flow Af-Arts but had only a
minimal effect in non-flow Af-Arts, eliminating
the difference between them. Symbols are: (0)
control (N = 9); (S) U-NAME (N = 8). p
0.013 and *p < 0.001, respectively, control
versus L-NAME-treated Af-Arts.
of the endothelium markedly augmented Ang IL-induced constric-
tion in free-flow Af-Arts (Fig. 3A); Ang II at 10— 10 10 i09,
and 10—8 M now caused luminal diameter to decrease to 88.5
2.2%, 79.7 3.4%, 67.0 5.1%, and 51.8 3.7% of baseline,
respectively (P < 0.001 vs. baseline for all concentrations). In
marked contrast, endothelial disruption had no effect on non-flow
Af-Arts (Fig. 3B). Consequently, after endothelial disruption,
Ang II caused almost identical constriction in free-flow and
non-flow Al-Arts.
Effect of NO synthesis inhibition
After L-NAME pretreatment, basal luminal diameter of both
free-flow and non-flow Al-Arts decreased significantly, dropping
by 18.6 4.1% (from 18.1 0.4 to 14.8 0.9 mm) and 16.6
4.3% (from 17.4 0.5 to 14.7 1.1 mm), respectively (N = 8).
Alter L-NAME treatment, Ang II at 10", 10'°, iO, and
i0 M caused luminal diameter of free-flow Al-Arts to decrease
to 89.3 1.9%, 82.1 2%, 66.3 3.1 and 45.9 2.5% of
baseline, respectively. The decrease in luminal diameter was
significantly greater compared with non-treated free-flow Af-Arts
at all doses (Fig. 4A). In contrast, L-NAME had only a minor
effect on non-flow Af-Arts (Fig. 4B). Thus, L-NAME also elimi-
nated the differences in Ang 11-induced constriction between
free-flow and non-flow Al-Arts.
Effect of cyclooxygenase inhibition
Indomethacin did not alter basal diameter of either free-flow or
non-flow Al-Arts (17.7 0.5 and 17.9 0.8 mm, respectively). It
did augment Ang lI-induced constriction; however, the effect was
far greater in free-flow Af-Arts, thus abolishing the differences in
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Fig. 5. Change in luminal diameter induced by
Ang II in free-flow (A) and non-flow (B) Af-Arts
in the absence (0, N = 9) and presence (•, N =
5) of indomethacin. Note that indomethacin
augmented Ang TI-induced constriction to a
greater degree in free-flow than non-flow Af-
Arts, eliminating the difference between them.p < 0.013 and * < 0.001, respectively,
control versus indomethacin-treated Al-Arts.
Discussion
We investigated whether flow per se can regulate Ang II- and
NE-induced vasoconstriction in the Af-Art, as well as the possible
mechanisms involved. Our findings suggest that Ang II- but not
NE-induced constriction is modulated by luminal flow. This effect
of flow on Ang II action requires an intact endothelium, since it
was eliminated by disrupting the endothelium. Furthermore, our
results suggest that intact synthesis of both NO and PGs is
necessary in order for flow to modulate Ang II action.
Although flow has been reported to cause both dilation and
constriction in various vascular beds [12, 18—20], the dominant
response to flow in large conduit arteries is dilation. Recently,
flow-induced dilation was also demonstrated at the arteriolar level
of the coronary [23—25], skeletal muscle [26], and mesenteric [27]
beds. In order to study directly whether flow modulates the
vasoconstrictor action of Ang II in the Af-Arts, we employed a
novel preparation in which free-flow and non-flow Af-Arts can be
observed simultaneously. We found that Ang IT-induced constric-
tion was significantly weaker in free-flow compared to non-flow
Af-Arts, suggesting that flow attenuates Ang II action in Af-Arts.
It could be argued that the stronger constriction observed in
non-flow Af-Arts is due to higher intraluminal pressure at the site
of measurements (and hence higher basal tone due to myogenic
response), since pressure would drop more steeply along free-flow
than non-flow Af-Arts. However, we consider this unlikely, since
Yuan, Robinette and Conger [28], using isolated and cannulated
Af-Arts with the distal end occluded (non-flow), have shown that
changing the intraluminal pressure from 90 to 30 mm Hg does not
alter the response to Ang II. In addition, we have previously
shown that increasing basal tone with norepinephrine does not
alter Ang II action in the Af-Art [3]. Furthermore, the differences
in Ang Il-induced constriction were abolished by endothelial
disruption, L-NAME, or indomethacin. Taken together, these
observations strongly suggest that the difference in Ang II action
in non-flow and free-flow Al-Arts is due to the presence or
absence of flow through the Af-Art.
Since the endothelium is strategically located at the interface
between the blood and the vessel wall, it is ideally situated to
sense changes in shear stress associated with flow and transmit!
transduce the signal to the vascular smooth muscle cells. It is
worth noting that flow has been found to evoke both endothelium-
dependent and -independent vascular responses [18—20, 23—25,
291. To study whether an intact endotheliun is required for flow
modulation of Ang II, we disrupted the endothelium using a
recently developed method that employs factor VITI-related an-
tigen antibodies and complement. We have previously shown that
this method eliminates endothelium-dependent vasodilation but
does not affect endothelium-independent vasodilation or constric-
tion [21]. In the present study, we found that disrupting the
endothelium augmented Ang TI-induced constriction in free-flow
but not non-flow Af-Arts, abolishing the difference between the
two. Thus our study demonstrates that flow modulation of Ang II
action in Af-Arts is dependent on an intact endothelium.
While flow has been reported to stimulate endothelial cells
(both in culture and in situ) to release NO [12—14] as well as PGI2
[13, 15—17], the factor(s) responsible for flow effects is apparently
tissue- and!or species-dependent. For example, Koller and Kaley
[26] found that flow-induced dilation in the vasculature of the rat
cremaster muscle was blocked by indomethacin, suggesting that
PGs are involved. On the other hand, Kuo et al [23—251 found that
in pig coronary microvessels, flow-induced dilation was unaffected
by indomethacin; rather, it was blocked by L-NMMA (an NO
synthesis inhibitor), suggesting that NO rather than PGs is
involved in flow-induced dilation. In the present study, we found
that L-NAME and indomethacin augmented Ang Il-induced
constriction to a similar extent in free-flow Al-Arts but had little
effect on non-flow Af-Arts. Interestingly, L-NAME or indometha-
cm alone completely abolished the difference between the two
Al-Arts, suggesting that both NO and PGs are necessary for flow
to modulate Ang II action in Af-Arts. This is consistent with our
previous finding that a combination of L-NAME and indometha-
cm had no additional effect over either one alone [4]. Taken
together, these studies may indicate that there is a significant
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exact mechanism of such an interaction is not clear, a mutual
dependency of NO and PGI2 actions has been reported. For
example, Shimokawa et al [30] reported that exogenous PG!2 or
forskolin relaxed porcine coronary artery strips more in the
presence of intact endothelium than in its absence, suggesting that
PGI2 (via cAMP) may stimulate NO release and/or act synergis-
tically with NO. In addition, Salvemini et a! [31] recently reported
that NO directly activates cyclooxygenase enzymes, while Graier
et a! [32] have shown that increased endothelial cAMP amplifies
agonist-induced synthesis of NO. It may be that under our
experimental conditions, flow greatly enhanced Ang Il-stimulated
synthesis of PG!2 and NO, resulting in a significant interactions
between them.
Despite strong modulation of Ang II action by flow via NO and
PGs, NE produced almost identical constriction in free-flow and
non-flow Af-Arts. This finding is consistent with our previous
studies in which L-NAME [3], indomethacin [4] and endothe-
lailization disruption [21] did not affect NE-induced constriction
in isolated perfused Af-Arts. On the other hand, we have previ-
ously shown that NE-induced constriction can be reversed by
acetylcholine and L-NAME blocks this dilation [3, 21]. Thus when
NO is stimulated to higher levels, it could modulate NE action in
the Af-Art. Furthermore, it has been reported that renal vasocon-
striction induced by intrarenal infusion of NE is augmented by
L-NAME [33]. Since a2-adrenergic receptors located on the
endothelium have been reported to be linked to NO synthesis
[34], we explored the possibility that the constrictor action of
intraluminal NE is modulated by NO in free-flow Af-Arts. We
found that while the vasoconstrictor action of intraluminal NE
tended to be weaker than extraluminal NE, L-NAME significantly
augmented it (Fig. 6). Taken together, these results suggest that
higher NO levels are needed to modulate NE action compared to
Ang II, possibly because NE has lesser effects on the synthesis of
PGs, which may interact with NO (even at lower levels) in a
synergistic manner (see above).
It is interesting to note that L-NAME significantly decreased
the basal diameter of both free-flow and non-flow Af-Arts,
whereas endothelial disruption with antibody/complement did not
constrict either one. These results are consistent with those of
Kuo et a! [23], who found that L-NAME constricted pig coronary
arterioles (non-flow), whereas mechanical de-endothelialization
did not. The reason for this apparent discrepancy may be that
endothelial disruption eliminates both dilating and constricting
factors derived from the endothelium, whereas L-NAME only
eliminates NO. Alternatively, L-NAME-induced vasoconstriction
may be due to inhibition of NO synthesis by Af-Art vascular
smooth muscle cells and/or some action(s) other than inhibition of
NO [35—37].
In view of our results suggesting that flow stimulates NO release
from Af-Art, it is interesting to note that L-NAME constricted
both non-flow and free-flow Af-Arts to the same extent. This
apparent contradiction might be explained by basal release of NO
that is present even at low- or non-flow states. Indeed, endothelial
cells in culture and vascular strips which are not exposed to flow
can release NO [38, 39]. In this respect, we previously found that
basal (myogenic) tone is not different between free-flow and
non-flow AS-Art at the flow rates generated by 60 mm Hg
perfusion pressure (as used in this study) or lower, whereas higher
flow rates significantly altered myogenic tone [40]. On the other
hand, we cannot completely rule out the possibility that L-NAME-
0 —9 —8
Norepinephrine,
Fig. 6. Change in luminal diameter induced by intraluminal NE in Af-Arts
in the absence (0) and presence (S) of L-NAME. Note that in contrast to
extraluminal NE, intraluminal NE-induced constriction in free-flow At-
Arts is significantly augmented by L-NAME. #P < 0.05 and *P < 0.01,
respectively, control versus L-NAME-treated Af-Arts.
induced vasoconstriction of these vessels is due to inhibition of
NO synthesis by Af-Art vascular smooth muscle cells and/or some
action(s) other than inhibition of NO. Despite similar reduction of
basal diameter (which may reflect NO activity) in free-flow and
non-flow Af-Arts, only in free-flow Af-Arts did L-NAME aug-
ment Ang II action. It may be that only in the presence of flow did
the decrease in basal diameter enhance NO synthesis by increas-
ing shear stress on the endothelium. Such increases in NO activity,
along with the unique interactions between NO and Ang II, may
have resulted in the L-NAME-induced augmentation of Ang II
action in free-flow Af-Arts.
Recent in vivo studies have shown that blockade of Ang II
action attenuates the increase in renal vascular resistance induced
by NO synthase inhibitors without affecting the increase in
systemic blood pressure [81. In addition, using two-kidney/one-clip
hypertensive rats, Sigmon and Beierwaltes [41] showed that the
more severe the stenosis, the less marked the L-NAME-induced
decrease in blood flow to the clipped kidney, indicating that the
amount of flow may determine NO dependency of renal hemo-
dynamics. These studies may suggest that there are significant
interactions between flow, NO and Ang II in the renal circulation.
Such interactions may be particulary important at the level of the
Af-Art, the vascular segment that accounts for the most of the
preglomerular resistance. The mechanism by which flow increases
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endothelium [13, 14, 171. Such a mechanism may be important in
such conditions as polycythemia, which is characterized by high
blood viscosity. Indeed, Wilcox et at [421 recently reported that in
rats with erythropoietin-induced polycythemia, renal blood flow
and GFR are within the normal range, while L-NAME-induced
renal vasoconstriction was greatly augmented compared with
normal rats, suggesting that heightened blood viscosity increases
shear stress on the endothelium and hence NO release, counter-
acting viscosity's effect to increase vascular resistance.
The present study demonstrates that the endothelium is impor-
tant in determining the action of Ang II in the Af-Art, and
provides further evidence supporting the role of NO and PGs in
the control of glomerular hemodynamics. Thus the status of the
endothelium may be a critical factor that determines renal
function under various physiological and pathological conditions
associated with heightened renin-angiotensin system. On the one
hand, when endothelial function is intact (such as during sodium
depletion), endogenous production of NO and PGs may prevent
excessive contraction of the Af-Art, while the Ef-Art would
constrict significantly since NO does not seem to modulate Ang II
action in this segment [31. Such differential interactions between
Ang II and NO/PGs may permit effective transmission of pressure
and flow to the glomerulus, thereby maintaining the GFR. On the
other hand, in pathological conditions where endothelial function
is impaired, such as ischemic acute renal failure [31, increased
Ang II may cause strong constriction of the Af-Art, resulting in
massive diminution of the GRF.
In conclusion, using a novel preparation which permits simul-
taneous observation of free-flow and non-flow Af-Arts, we have
driectly tested whether flow through the lumen affects Af-Art
responses to Ang II. Our results indicate that flow does indeed
attenuate Ang II action via endothelial production of NO and
PGs. Thus our study demonstrates the existence of dynamic
interactions between flow, the endothelium and Ang H in the
control of glomerular hemodynamics. Further studies are needed
in order to clarify the role of endothelium-derived NO and PGs in
the control of glomerular hemodynamics under various physio-
logical and pathological conditions.
Acknowledgments
This study was supported by NIH grants HL46518 and HL28982. S. Ito
and J. Garvin are recipients of an Established Investigatorship Award of
the American Heart Association and Research Career Developmental
Award of NIH, respectively.
Reprint requests to Luis A. Juncos, M.D., Hypertension and Vascular
Research Division, Henty Ford Hospital, 2799 West Grand Boulevard,
Detroit, Michigan 48202, USA.
References
1. ICHIKAWA I, HARRIS RC: Angiotensin actions in the kidney: Renewed
insight into the old hormone. Kidney mt 40:583—596, 1991
2. ITo S, JOHNSON C, CARRETERO OA: Modulation of angiotensin
lI-induced vasoconstriction by endothelium-derived relaxing factor in
the isolated perfused rabbit afferent arteriole. J C/in Invest 87:1656—
1663, 1991
3. ho S, ARIMA S, REN Y, JUNCOS LA, CARRETERO OA: Endothelium-
derived rclaxing factor/nitric oxide modulates angiotensin TI action in
the isolated microperfused rabbit afferent but not efferent arteriole. J
Clin Invest 91:2012—20193, 1993
4. ARIMA S, RuN Y, JUNCOS LA, CARRETER0 OA, ITO S: Glomerular
prostaglandins modulate vascular reactivity of the downstream effer-
ent arterioles. Kidney mt 45:650—658, 1994
5. BAYLIS C, BRENNER BM: Modulation by prostaglandin synthesis
inhibitors of the action of exogenous angiotensin II on glomerular
ultrafiltration in the rat. Circ Res 43:889—898, 1978
6. DUNN JM, SCHARSCHMIDT LA: Prostaglandins modulate the glomer-
ular action of angiotensin II. Kidney Jot 31(Suppl 20):S95—S101, 1987
7. D NICOLA L, BLANTZ R, GABBAI F: Nitric oxide and angiotensin II.
Glomerular and tubular interaction in the rats. J C/in Invest 89:1248—
1256, 1992
8. SIGMON D, CARRETERO OA, BELERWALTES WH: Angiotensin depen-
dence of endothelium-mediated renal hemodynamics. Hypertension
20:643—650, 1992
9. PELAYO JC: Renal adrenergic effector mechanisms: glomerular sites
for prostaglandin interaction. Am J Physio/ 254:F184—F190, 1988
10. MULLANE KM, MONCADA S: Prostacyclin release and the modulation
of some vasoactive hormones. Prostag/andins 20:25—49, 1980
11. HASEGAWA K, NISHIMURA H, KHOSLA HC: Angiotensin II causes
endothelium-dependent relaxation in fowl aorta. Am J Physio/ 244:
F526—F534, 1993
12. RUBANYI G, ROMERO JC, VANHOUTFE P: Flow-induced release of
endothelium-derived relaxing factor. Am J Physiol 250:H1 145—Hl 149,
1986
13. NOLLERT M, DIAMOND S, MCINTIRE L: Hydrodynamic shear stress
and mass transport modulation of endothelial cell metabolism. Bio-
tech Bioeng 38:588—602, 1991
14. BUGA G, GOLD M, FUKUTO J, IGNARRO L: Shear stress-induced
release of nitric oxide from endothelial cells grown on beads. Hyper-
tension 17:187—193, 1991
15. VAN GRONDELLE A, WORTHEN G, ELLIS D, MATHIAS M, MURPHY R,
STREIFL R, REEVES J, VOELKEL N: Altering hemodynamic variables
influences PGI2 production by isolated lungs and endothelial cells. J
Appi Physio/ 57:388—395, 1984
16. FRANGOS J, ESKIN S, MCINTIRE L, IVES C: Flow effects on prostacyclin
production by cultured human endothelial cells. Science 227:1477—
1479, 1985
17. BHAGYALAKSHMI A, FRANGOS J: Mechanism of shear-induced prosta-
cyclin production in endothelial cells. Biochem Biophys Res Commun
158:31—37, 1989
18. POHL U, HOLTZ J, BUSSE R, BASSENGE E: Crucial role of the
endothelium in the vasodilation response to increased flow in vivo.
Hypertension 8:37—44, 1986
19. BEVAN J, LAHER I: Pressure and flow-dependent vascular tone.
FASEB J 5:2267—2273, 1991
20. GARCIA-ROLDAN JL, BEVAN J: Flow-induced constriction and dilation
of cerebral resistance arteries. Circ Res 66:1445—1448, 1990
21. JUNCOS LA, ITO S, CARRETERO GA, GARVIN J: Removal of endothe-
hum-dependent relaxation by antibody and complement in afferent
arterioles. Hypertension 23(Suppl l):154—159, 1994
22. ITOH S, CARRETERO OA: Role of the macula densa in renin release.
Hypertension 7(Suppl I):149—154, 1985
23. Kuo L, CHILIAN WM, DAVIS Mi: Interaction of pressure- and
flow-induced responses in porcine coronary resistance vessels. Am J
Physio/ 261:H1706—H1715, 1991
24. Kuo L, ARKO F, CHILIAN WM, DAVIS MJ: Coronary venular re-
sponses to flow and pressure. Circ Res 72:607—615, 1993
25. KUO L, CHILIAN WM, DAVIS MJ: Endothelium-dependent, flow-
induced dilation of isolated coronary arterioles. Am J Physiol 259:
H1063—H1070, 1990
26. KOLLER A, KALEY G: Prostaglandins mediate arteriolar dilation to
increased blood flow velocity in skeletal muscle microcirculation. Circ
Res 67:529-534, 1990
27. SMIESKO V, LANG D, JOHNSON P: Dilator response of rat mesentcric
arcading arterioles to increased blood flow velocity. Am J Physio/
257:H1958—H1965, 1989
28. YUAN B, ROBINEYFE J, CONGER J: Effect of angiotensin II and
norepinephrine on isolated rat afferent and efferent arterioles. Am J
Physiol 258:F74I—F750, 1990
29. BEVAN J, JOYCE E, WELLMAN G: Flow-dependent dilation in resis-
tance artery still occurs after endothelium removal. Circ Res 63:980—
985, 1988
Juncos et al. Flow modulates Ang II in afferent arterioles 381
30. SHIMOKAWA H, FLAVAHAN NA, LORENZ RR, VANHOUTE PM: Pros-
tacyclin releases endothelium-derived relaxing factor and potentiates
its action in coronary arteries of the pig. BrJ Pharmacol 95:1197—1203,
1988
31. SvEMINI D, MisKo TP, MASFERRER JL, SEIBERT K, CURRIE MG,
NEEDLEMAN P: Nitric oxide activates cyclooxygenase enzymes. Proc
Natl ..4cad Sci USA 90:7240—7244, 1993
32. GRAIER WF, GROSCHNER K, SCHMIDT K, KUKOVETS WR: Increases in
endothelial cyclic AMP levels amplify agonist-induced formation of
endothelium-derived relaxing factor (EDRF). Biochem J 288:345—349,
1992
33. GRANGER JP, ALBEROLA AM, SALAZAR FJ, NAKAMURA T: Control of
renal hemodynamics during intrarenal and systemic blockade of nitric
oxide in conscious dogs. J Cardiovas Pharmacol 20(Suppl 12):S160—
S162, 1992
34. RICHARD B, TANNER FC, TSCHUDI M, LUSCHER TF: Different activa-
tion of L-Arginine pathway by bradykinin, serotonin, and clonidine.
Am J Physiol 259:H1433—H1439, 1990
35. THOMAS G, RAMWELL P: Interaction of non-arginine compounds with
the endothelium-derived relaxing factor inhibitor, N°-monomethyl-L-
arginine. J Pharmocol Exp Ther 260:676—679, 1992
36. ROSENBLUM W, NISHIMURA H, NELSON G: L-NMMA in brain micro-
circulation of mice is inhibited by blockade of cyclooxygenase and by
superoxide dismutase. Am J Physiol 262:H1343—H1349, 1992
37. KATUSIC Z: Endothelium-independent contractions to N°-mono-
methyl-L-arginine in canine basilar artery. Stroke 22:1399—1404, 1991
38. MONCADA S, PALMER R, HIGGS EA: Nitric oxide: Physiology, patho-
physiology, and pharmacology. Pharmacol Rev 43:109—142, 1991
39. MONCADA S, PALMER R, HIGGS EA: The discovery of nitric oxide as
the endogenous nitrovasodilator. Hypertension 12:365—372, 1988
40. JUNCOS LA, GARVIN J, CARRETERO OA, ITO S: Flow modulates
myogenic responses in isolated microperfused rabbit afferent arte-
rioles via endothelium-derived nitric oxide. J Clin Invest 95:2741—2748,
1995
41. SIGMON DH, BEIERWALTES WH: Degree of renal artery stenosis alters
nitric oxide regulation of renal hemodynamics. J Am Soc Nephrol
5:1369—1377, 1994
42. WILCOX CS, DENG X, DOLL AH, SNELLEN H, WELCH WJ: Nitric oxide
mediates renal vasodilation during erythropoietin-induced polycythe-
mia. Kidney mt 44:430—435, 1993
43. CONGER J, ROBINErFE J, SCHRIER RW: Smooth muscle calcium and
endothelium-derived relaxing factor in the abnormal vascular re-
sponses of acute renal failure. J Clin Invest 82:532—537, 1988
